SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Titel:
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Auteur:
Ober Shepherd, Brittany L Scott, Paul T Hutter, Jack N Lee, Christine McCauley, Melanie D Guzman, Ivelese Bryant, Christopher McGuire, Sarah Kennedy, Jessie Chen, Wei-Hung Hajduczki, Agnes Mdluli, Thembi Valencia-Ruiz, Anais Amare, Mihret F Matyas, Gary R Rao, Mangala Rolland, Morgane Mascola, John R De Rosa, Stephen C McElrath, M Juliana Montefiori, David C Serebryannyy, Leonid McDermott, Adrian B Peel, Sheila A Collins, Natalie D Joyce, M Gordon Robb, Merlin L Michael, Nelson L Vasan, Sandhya Modjarrad, Kayvon